littl
known
adenoviru
infect
adult
lung
transplant
recipi
viru
establish
latenc
reactiv
may
rel
common
transplant
assess
adenoviru
infect
adult
lung
transplant
recipi
adenoviru
polymeras
chain
reaction
realtim
pcr
assay
limit
detect
copiesml
plasma
done
plasma
sampl
collect
regular
interv
year
posttranspl
adenoviru
dna
detect
patient
plasma
sampl
month
posttranspl
median
time
detect
viremia
day
posttranspl
rang
day
median
viral
load
copiesml
plasma
rang
copiesml
symptom
evalu
time
adenoviru
detect
patient
asymptomat
patient
otherwis
unexplain
febrileflulik
ill
resolv
spontan
adenoviru
found
trigger
acut
reject
detriment
effect
pulmonari
function
seen
immedi
adenoviru
infect
conclus
adenoviru
viremia
common
adult
lung
transplant
recipi
contrast
find
adenovir
pneumon
lung
transplant
recipi
isol
episod
lowlevel
viremia
selflimit
trigger
acut
reject
declin
pulmonari
function
adenovirus
doublestrand
dna
virus
serotyp
known
caus
human
infect
includ
respiratori
syndrom
gastrointestin
diseas
febril
syndrom
immunocompet
host
infect
lifelong
immun
appear
serotypespecif
therefor
infect
serotyp
may
occur
addit
viru
establish
latenc
numer
tissu
includ
tonsil
adenoid
intestin
urinari
tract
therefor
transplant
patient
may
risk
adenoviru
infect
either
new
acquisit
reactiv
latent
viru
transplant
patient
spectrum
clinic
sequela
due
adenoviru
infect
seem
broad
may
also
differ
pediatr
adult
popul
children
acquisit
new
virus
may
common
wherea
adult
reactiv
endogen
latent
viru
may
like
occur
sever
lifethreaten
dissemin
diseas
well
describ
adult
pediatr
hematopoiet
stem
cell
recipi
solidorgan
recipi
overal
lung
transplant
recipi
adenoviru
infect
appear
high
risk
sever
necrot
pneumon
result
signific
graft
dysfunct
associ
high
mortal
infect
allograft
adenoviru
also
associ
acut
chronic
reject
graft
dysfunct
studi
lung
heart
transplant
recipi
howev
recent
data
suggest
adenoviru
reactiv
viremia
may
rel
common
transplant
recipi
case
may
associ
advers
clinic
sequela
especi
evid
allograft
infect
undertook
present
studi
assess
incid
time
clinic
sequela
adenoviru
viremia
lung
transplant
recipi
patient
studi
enrol
part
clinic
trial
compar
valganciclovir
prophylaxi
ganciclovir
intraven
oral
cytomegaloviru
cmv
prophylaxi
r
r
lung
transplant
recipi
design
previou
studi
regard
inclus
exclus
criteria
describ
detail
elsewher
patient
enrol
two
canadian
transplant
center
transplant
institut
review
board
center
approv
studi
inform
consent
obtain
patient
origin
studi
evalu
cmv
prophylaxi
part
studi
patient
receiv
oral
ganciclovir
intraven
ganciclovir
oral
valganciclovir
month
posttranspl
patient
group
plasma
sampl
save
test
regular
interv
posttranspl
initi
done
usual
everi
week
monthli
interv
plasma
sampl
underw
adenoviru
test
use
quantit
realtim
polymeras
chain
reaction
pcr
assay
see
later
cmv
viral
load
test
quantit
pcr
roch
coba
amplicor
assay
roch
diagnost
system
branchburg
nj
result
viral
load
test
adenoviru
cmv
avail
treat
physician
pretranspl
sampl
avail
test
part
studi
first
year
protocol
bronchoscopi
perform
one
two
particip
center
took
place
week
posttranspl
month
posttranspl
routin
microbiolog
test
perform
well
transbronchi
biopsi
assess
reject
two
set
primer
probe
design
highli
conserv
hexon
gene
adenoviru
type
use
primerexpress
softwar
abi
design
detect
serotyp
dna
extract
l
plasma
use
qiagen
dna
minikit
accord
manufactur
protocol
qiagen
elut
column
l
elut
buffer
quantifi
adenoviru
plasma
extern
standard
curv
establish
seri
dilut
one
copi
copi
use
dna
fragment
produc
type
adenoviru
realtim
taqman
pcr
conduct
closedtub
sequenc
detect
system
model
abipr
appli
biosystem
briefli
pcr
perform
volum
contain
l
univers
dna
master
mix
appli
biosystem
l
dna
nmollit
primer
nmollit
probe
initi
incub
minut
activ
uracilnglycosylas
minut
denatur
pcr
amplif
perform
twostep
thermal
cycl
second
minut
cycl
reheat
minut
amplif
data
collect
analyz
comput
sequenc
detect
system
version
appli
biosystem
dynam
rang
detect
pcr
copiesml
plasma
normal
healthi
control
adenoviru
dna
detect
plasma
sampl
use
assay
patient
detect
adenoviru
viremia
pcr
clinic
diseas
attribut
adenoviru
detect
viremia
accompani
compat
symptom
includ
febril
ill
respiratori
gastrointestin
diseas
evid
infect
allograft
absenc
anoth
defin
etiolog
addit
complic
microbiolog
data
first
year
posttranspl
assess
determin
whether
adenoviru
infect
diagnos
clinic
outsid
studi
evalu
acut
reject
grade
diagnos
basi
transbronchi
biopsi
demonstr
characterist
perivascular
lymphocyt
infiltr
use
criteria
defin
intern
societi
heart
lung
transplant
ishlt
patient
biopsi
could
perform
clinic
diagnosi
reject
permit
ie
deterior
lung
function
identifi
etiolog
respond
highdos
corticosteroid
therapi
effect
pulmonari
function
patient
adenoviru
infect
determin
base
measur
forc
expiratori
volum
second
fev
fev
declin
within
month
adenoviru
infect
consid
potenti
signific
occur
within
time
period
viral
trigger
declin
graft
function
may
play
role
cmv
diseas
defin
accord
standard
criteria
inform
consent
obtain
patient
particip
studi
clinic
research
conduct
accord
institut
guidelin
human
experiment
total
lung
transplant
recipi
analyz
doublelung
singlelung
transplant
recipi
tabl
total
plasma
sampl
test
mean
number
sampl
per
patient
rang
mean
age
year
rang
includ
women
men
pretranspl
underli
lung
diseas
includ
cystic
fibrosi
n
emphysema
chronic
obstruct
pulmonari
diseas
copd
n
idiopath
pulmonari
fibrosi
n
antitrypsin
defici
n
n
mainten
immunosuppress
cyclosporineprednisoneazathioprin
n
cyclosporineprednisonemycophenol
n
n
total
patient
receiv
induct
antilymphocyt
globulin
cmv
prophylaxi
consist
intraven
ganciclovir
week
patient
follow
week
oral
ganciclovir
n
intraven
ganciclovir
n
oral
valganciclovir
n
adenoviru
dna
detect
patient
first
month
posttranspl
total
sampl
test
patient
posit
quantit
viral
load
data
shown
figur
median
viral
load
copiesml
rang
copiesml
viremia
detect
one
occas
patient
two
occas
patient
time
viremia
posttranspl
shown
figur
rel
evenli
distribut
throughout
first
year
posttranspl
median
time
detect
first
viremia
day
posttranspl
rang
day
donor
specif
test
adenoviru
donor
chart
review
case
viru
detect
earli
recipi
reveal
clinic
radiolog
evid
activ
infect
donor
symptom
review
time
viremia
patient
viremia
symptom
time
viremia
four
patient
symptom
symptom
consist
febril
flulik
ill
patient
clinic
radiolog
evid
pneumon
time
viremia
adenoviru
pneumon
document
studi
patient
studi
period
patient
viremia
symptom
etiolog
symptom
found
nega
tive
cmv
antigenemia
case
symptom
resolv
spontan
without
specif
therapi
without
chang
immunosuppress
adenoviru
viral
load
compar
symptomat
vs
asymptomat
patient
median
viral
load
copiesml
patient
symptom
rang
vs
copiesml
asymptomat
patient
rang
p
signific
ns
underli
diseas
patient
cystic
fibrosi
n
idiopath
pulmonari
fibrosi
n
emphysema
n
immunosuppress
consist
cyclosporin
prednison
azathioprin
patient
low
viral
load
observ
present
studi
contrast
high
viral
load
observ
clinic
set
among
transplant
patient
document
adenovir
pneumon
previou
respiratori
viru
season
patient
kidney
transplant
recipi
lung
transplant
recipi
neither
part
studi
diagnos
adenoviru
pneumon
viral
load
patient
copiesml
plasma
respect
risk
factor
viremia
also
analyz
tabl
specif
epidemiolog
link
observ
patient
viremia
evid
season
appar
adenoviru
infect
found
trigger
acut
reject
clinic
treat
biopsi
proven
overal
incid
one
acut
reject
episod
patient
adenoviru
viremia
vs
nonvirem
patient
p
case
episod
acut
reject
develop
within
month
viremia
wherea
case
reject
episod
occur
viremia
patient
viremia
pulmonari
function
test
fev
remain
stabl
immedi
month
detect
viremia
interact
develop
cmv
viremia
symptomat
cmv
diseas
observ
cmv
viremia
occur
patient
adenoviru
vs
patient
without
adenoviru
p
ns
symptomat
cmv
diseas
occur
patient
adenoviru
vs
patient
without
adenoviru
p
ns
patient
adenoviru
cmv
viremia
n
cmv
preced
adenoviru
patient
occur
adenoviru
patient
mean
peak
cmv
viral
load
patient
adenoviru
copiesml
rang
undetect
copiesml
vs
copiesml
rang
undetect
copi
ml
patient
without
adenoviru
p
ns
cmv
prophylaxi
influenc
detect
adenoviru
viremia
number
patient
posit
anticmv
prophylaxi
similar
rate
posit
discontinu
prophylaxi
shown
adenoviru
viremia
common
lung
transplant
recipi
detect
patient
first
year
posttranspl
major
infect
associ
symptom
patient
symptom
like
attribut
adenoviru
present
consist
febril
flulik
ill
patient
symptom
resolut
occur
without
use
antivir
therapi
reduct
immunosuppress
viral
load
gener
low
patient
rang
copiesml
viremia
sustain
howev
repres
true
replic
infect
rather
detect
latent
viru
cellfre
sampl
ie
plasma
use
viral
detect
adenoviru
viremia
associ
evid
indirect
effect
graft
function
presenc
acut
reject
result
contrast
previou
report
adenoviru
infect
lung
transplant
recipi
exampl
studi
pediatr
lung
heartlung
recipi
specimen
swab
bronchoalveolar
lavag
fluid
prospect
test
respiratori
virus
cultur
pcr
antigen
detect
patient
adenoviru
identifi
transplant
lung
patient
patient
appear
donortransmit
earli
fulmin
adenoviru
pneumon
overal
adenoviru
infect
transplant
lung
significantli
associ
graft
loss
oblit
bronchiol
ob
death
due
respiratori
failur
anoth
studi
biopsi
autopsi
specimen
analyz
adenoviru
immunohistochemistri
situ
hybrid
lung
transplant
recipi
adenoviru
pneumon
identifi
patient
case
sever
necrot
pneumonia
fatal
three
case
pediatr
transplant
recipi
case
occur
within
day
transplant
suggest
either
donor
transmiss
earli
acquisitionreactiv
recipi
late
fatal
adenoviru
pneumon
occur
sever
year
lung
transplant
also
describ
pcr
assay
use
sensit
copiesml
would
expect
significantli
sensit
cultur
direct
antibodi
stain
method
commonli
use
respiratori
specimen
also
assess
blood
sampl
oppos
respiratori
specimen
factor
may
partial
account
higher
rate
infect
observ
compar
studi
respiratori
viral
infect
adult
lung
transplant
recipi
long
suspect
potenti
trigger
allograft
reject
develop
oblit
bronchiol
clinic
equival
bronchiol
obliteran
syndrom
bo
take
account
limit
recent
studi
small
retrospect
sampl
size
literatur
support
associ
respiratori
viru
infect
bo
exampl
khalifah
et
al
retrospect
review
lung
transplant
recipi
respiratori
sampl
cultur
antigen
detect
found
respiratori
viral
infect
includ
case
adenoviru
respiratori
tract
infect
patient
increas
risk
bo
death
kumar
et
al
prospect
studi
lung
transplant
patient
includ
patient
respiratori
viru
infect
control
respiratori
specimen
molecular
detect
method
pcr
use
addit
standard
viral
techniqu
adenoviru
identifi
patient
common
etiolog
viral
infect
rhinoviru
coronaviru
respiratori
syncyti
viru
rsv
influenza
viral
infect
associ
acut
reject
signific
declin
fev
time
consist
develop
bo
evid
organ
recipi
adenoviru
infect
allograft
may
associ
indirect
effect
shirali
et
al
perform
viral
pcr
endomyocardi
biopsi
pediatr
heart
transplant
recipi
found
adenoviru
commonli
detect
viru
found
patient
viral
detect
associ
increas
risk
coronari
vasculopathi
graft
loss
overal
data
adenoviru
infect
lung
transplant
recipi
suggest
infect
sever
especi
pediatr
patient
associ
necrot
pneumonia
result
declin
pulmonari
function
howev
data
suggest
adult
infect
common
often
asymptomat
associ
mild
selflimit
symptom
discrep
may
due
sever
factor
first
assess
viremia
rather
infect
within
allograft
may
two
site
infect
behav
differ
term
symptomatolog
clinic
consequ
second
use
activ
molecular
surveil
techniqu
like
pick
subclin
case
compar
symptombas
diagnost
evalu
third
assess
pediatr
patient
may
like
newli
acquir
adenoviru
absenc
preexist
immun
therefor
emphas
although
signific
clinic
effect
lowlevel
viremia
observ
patient
higher
viral
load
may
well
sever
diseas
associ
reject
possibl
case
adenoviru
detect
may
due
reactiv
previous
latent
viru
howev
possibl
newli
acquir
adenoviru
due
exogen
exposur
exclud
result
consist
recent
publish
molecular
surveil
data
organ
transplant
recipi
studi
adult
kidney
kidneypancrea
liver
heart
transplant
recipi
test
blood
sampl
regular
interv
incid
detect
viremia
patient
viremia
asymptomat
wherea
remain
patient
viremia
associ
selflimit
respiratori
gastrointestin
symptom
studi
investig
detect
associ
subsequ
allograft
reject
limit
studi
includ
small
sampl
size
fix
test
interv
exampl
test
may
necessarili
carri
timepoint
patient
may
compat
symptom
eg
respiratori
gastrointestin
symptom
therefor
possibl
incid
infect
may
even
higher
addit
case
adenoviru
clinic
diagnos
patient
posit
surveil
howev
specif
pcr
test
adenoviru
routin
perform
clinic
purpos
studi
period
final
studi
consid
substudi
part
cmv
prophylaxi
studi
adenoviru
surveil
primari
object
conclus
adenoviru
viremia
common
adult
lung
transplant
recipi
infect
may
differ
allograft
primarili
involv
virem
episod
either
asymptomat
associ
selflimit
febril
syndrom
despit
chang
immunosuppress
specif
antivir
therapi
associ
acut
reject
episod
declin
lung
function
observ
infect
present
routin
pcr
surveil
lung
transplant
would
indic
base
data
present
although
studi
requir
